172 related articles for article (PubMed ID: 30950925)
1. Effect of metformin on the risk of prostate cancer in patients with type 2 diabetes by considering different confounding factors: a meta-analysis of observational studies.
Wang Y; Liu X; Yan P; Tang J; Chen T; Sun Y; Zhou W; Bi Y; Zhang ZJ
Eur J Cancer Prev; 2020 Jan; 29(1):42-52. PubMed ID: 30950925
[TBL] [Abstract][Full Text] [Related]
2. Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis.
Kowall B; Rathmann W; Kostev K
Diabetes Care; 2015 Jan; 38(1):59-65. PubMed ID: 25336750
[TBL] [Abstract][Full Text] [Related]
3. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK.
Kowall B; Stang A; Rathmann W; Kostev K
Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):865-74. PubMed ID: 26132313
[TBL] [Abstract][Full Text] [Related]
4. Risk of hypoglycemia following intensification of metformin treatment with insulin versus sulfonylurea.
Roumie CL; Min JY; Greevy RA; Grijalva CG; Hung AM; Liu X; Elasy T; Griffin MR
CMAJ; 2016 Apr; 188(6):E104-E112. PubMed ID: 26811361
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer.
Häggström C; Van Hemelrijck M; Zethelius B; Robinson D; Grundmark B; Holmberg L; Gudbjörnsdottir S; Garmo H; Stattin P
Int J Cancer; 2017 Feb; 140(3):611-617. PubMed ID: 27770555
[TBL] [Abstract][Full Text] [Related]
6. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
Currie CJ; Poole CD; Gale EA
Diabetologia; 2009 Sep; 52(9):1766-77. PubMed ID: 19572116
[TBL] [Abstract][Full Text] [Related]
7. Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study.
Au Yeung SL; Schooling CM
BMJ Open Diabetes Res Care; 2019; 7(1):e000872. PubMed ID: 31908803
[TBL] [Abstract][Full Text] [Related]
8. Association between metformin therapy and incidence, recurrence and mortality of prostate cancer: evidence from a meta-analysis.
Deng D; Yang Y; Tang X; Skrip L; Qiu J; Wang Y; Zhang F
Diabetes Metab Res Rev; 2015 Sep; 31(6):595-602. PubMed ID: 25708557
[TBL] [Abstract][Full Text] [Related]
9. Metformin and the incidence of prostate cancer in patients with type 2 diabetes.
Azoulay L; Dell'Aniello S; Gagnon B; Pollak M; Suissa S
Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):337-44. PubMed ID: 21148757
[TBL] [Abstract][Full Text] [Related]
10. Metformin use and prostate cancer risk: A meta-analysis of cohort studies.
Feng Z; Zhou X; Liu N; Wang J; Chen X; Xu X
Medicine (Baltimore); 2019 Mar; 98(12):e14955. PubMed ID: 30896668
[TBL] [Abstract][Full Text] [Related]
11. Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus.
Tseng CH
Diabetes Metab Res Rev; 2015 Sep; 31(6):619-26. PubMed ID: 25820555
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
[TBL] [Abstract][Full Text] [Related]
13. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.
Tseng CH
Eur J Cancer; 2014 Nov; 50(16):2831-7. PubMed ID: 25201464
[TBL] [Abstract][Full Text] [Related]
14. Effects of three injectable antidiabetic agents on glycaemic control, weight change and drop-out in type 2 diabetes suboptimally controlled with metformin and/or a sulfonylurea: A network meta-analysis.
Zhong X; Zhang T; Liu Y; Wei X; Zhang X; Qin Y; Jin Z; Chen Q; Ma X; Wang R; He J
Diabetes Res Clin Pract; 2015 Sep; 109(3):451-60. PubMed ID: 26233934
[TBL] [Abstract][Full Text] [Related]
15. An economic evaluation of colesevelam when added to metformin-, insulin- or sulfonylurea-based therapies in patients with uncontrolled type 2 diabetes mellitus.
Simons WR; Hagan MA
Pharmacoeconomics; 2010; 28(9):765-80. PubMed ID: 20799756
[TBL] [Abstract][Full Text] [Related]
16. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
Fonseca V; Gill J; Zhou R; Leahy J
Diabetes Obes Metab; 2011 Sep; 13(9):814-22. PubMed ID: 21481127
[TBL] [Abstract][Full Text] [Related]
17. Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort.
Vihervuori VJ; Talala K; Taari K; Lahtela J; Tammela TLJ; Auvinen A; Raittinen P; Murtola TJ
Cancer Epidemiol Biomarkers Prev; 2021 May; 30(5):982-989. PubMed ID: 33653815
[TBL] [Abstract][Full Text] [Related]
18. The effect of metformin on esophageal cancer risk in patients with type 2 diabetes mellitus: a systematic review and meta‑analysis.
Wu HD; Zhang JJ; Zhou BJ
Clin Transl Oncol; 2021 Feb; 23(2):275-282. PubMed ID: 32507907
[TBL] [Abstract][Full Text] [Related]
19. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes.
Roumie CL; Greevy RA; Grijalva CG; Hung AM; Liu X; Murff HJ; Elasy TA; Griffin MR
JAMA; 2014 Jun; 311(22):2288-96. PubMed ID: 24915260
[TBL] [Abstract][Full Text] [Related]
20. Historical cohort analysis of treatment patterns for patients with type 2 diabetes initiating metformin monotherapy.
Hazel-Fernandez L; Xu Y; Moretz C; Meah Y; Baltz J; Lian J; Kimball E; Bouchard J
Curr Med Res Opin; 2015; 31(9):1703-16. PubMed ID: 26154837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]